|Quest Diagnostics Announces Proposed Senior Notes Offering|
|MADISON, N.J., May 23, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $500,000,000 aggregate principal amount of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.
The issuance of the notes will be subject to customary closing conditions. The company int... ||05/23/16|
|Quest Diagnostics Declares Quarterly Cash Dividend|
|MADISON, N.J., May 18, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share, payable on July 20, 2016 to shareholders of record of Quest Diagnostics common stock on July 6, 2016.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinic... ||05/18/16|
|Quest Diagnostics Completes Effort to Refocus on Diagnostic Information Services; Updates 2016 Revenue Outlook|
|- Strategy to refocus business portfolio completed with sale of Focus Diagnostics products business for $300 million
- Full Year 2016 revenue now expected to be between $7.47 billion and $7.54 billion, reflecting sale
- Full year 2016 EPS outlook remains unchanged
MADISON, N.J., May 18, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed efforts to refocus its business on diagnostic ... ||05/18/16|
|DiaSorin S.p.A. Completes Acquisition of the Focus Diagnostics' Molecular and Immunoassay Product Business from Quest Diagnostics|
|SALUGGIA, Italy, May 13, 2016 /PRNewswire/ -- DiaSorin S.p.A. (FTSE Italy: DIA) today announced the completion of the transaction to acquire the Focus Diagnostics' immunodiagnostic and molecular diagnostic products business ("Focus") from Quest Diagnostics (NYSE: DGX), initiated with a binding purchase agreement signed on March 29, 2016.
DiaSorin paid to Quest Diagnostics $300 million in cash for all the tangible and intangible assets of Focus used by the latter to develop, manufacture and... ||05/13/16|